| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 8.7 |
| Profit before tax | -21.1 | -20.6 |
| Net income | -21.1 | -20.4 |
| EPS (diluted, $ a share) | $-0.56 | $-0.55 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -74.8% |
|---|
10-Q filed with the SEC, NASDAQ: MGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Metagenomi Therapeutics, Inc.: key numbers
- Share price
- $0.6310Close, Nov 17
- Market cap
- $23.9M
- Shares outstanding
- 37.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Metagenomi Therapeutics, Inc.
All →Metagenomi Therapeutics Investor Presentation
Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.
Metagenomi Therapeutics Regulatory Approval
Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.
“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”
Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
Metagenomi Therapeutics Investor Presentation
Metagenomi Therapeutics, Inc. filed a corporate presentation dated September 2026 as an exhibit to its 8-K. The presentation outlines the company's strategy for precision gene editing and the development of curative medicines. The filing is a standard Regulation FD disclosure used to provide updated information to investors and analysts.